Teva���s U.S. Generic-Drug Sales Tumble on Factory Problems

injected medicine has had to compete since September against the first pill approved in the U.S. for multiple sclerosis, Novartis AG���s Gilenya. ���The core business is either declining, or under great risk,��� Gilad Alper, an analyst for Meitav...